CL2007003143A1 - Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion. - Google Patents
Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion.Info
- Publication number
- CL2007003143A1 CL2007003143A1 CL2007003143A CL2007003143A CL2007003143A1 CL 2007003143 A1 CL2007003143 A1 CL 2007003143A1 CL 2007003143 A CL2007003143 A CL 2007003143A CL 2007003143 A CL2007003143 A CL 2007003143A CL 2007003143 A1 CL2007003143 A1 CL 2007003143A1
- Authority
- CL
- Chile
- Prior art keywords
- solubilizer
- diluent
- indole
- pharmaceutical composition
- dosage form
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003085 diluting agent Substances 0.000 title abstract 4
- 239000002904 solvent Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title abstract 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Composición farmacéutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepración; y forma de dosificación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85566306P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003143A1 true CL2007003143A1 (es) | 2008-01-25 |
Family
ID=39345039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2007003143A CL2007003143A1 (es) | 2006-10-31 | 2007-10-30 | Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100113443A1 (es) |
| EP (1) | EP2104498A2 (es) |
| JP (1) | JP2010508302A (es) |
| AR (1) | AR063743A1 (es) |
| AU (1) | AU2007313706A1 (es) |
| BR (1) | BRPI0717943A2 (es) |
| CL (1) | CL2007003143A1 (es) |
| PE (1) | PE20081408A1 (es) |
| TW (1) | TW200824712A (es) |
| WO (1) | WO2008055136A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2614144B1 (en) | 2010-09-08 | 2015-07-22 | Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
| GB201401904D0 (en) * | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622832A (en) * | 1990-02-28 | 1997-04-22 | Genetics Institute, Inc. | Arachidonic acid releasing phospholipase A2 enzyme and methods of use |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| EP1039893B1 (en) * | 1997-12-10 | 2011-02-02 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| US6352718B1 (en) * | 1999-09-27 | 2002-03-05 | American Cyanamid Company | Vasopressin antagonist formulation and process |
| DE60233150D1 (de) * | 2001-10-19 | 2009-09-10 | Isotechnika Inc | Neue cyclosporin-analoge mikroemulsionsvorkonzentrate |
| US6984735B2 (en) * | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
| US7605156B2 (en) * | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
| US6797708B2 (en) * | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
| US20050002158A1 (en) * | 2002-02-25 | 2005-01-06 | Robert Olodort | Mobile computer with foldable keyboard |
| TW200510305A (en) * | 2003-07-25 | 2005-03-16 | Wyeth Corp | Process for the preparation of CPLA2 inhibitors |
| US7582771B2 (en) * | 2003-09-03 | 2009-09-01 | Wyeth | Process for the synthesis of cPLA2 inhibitors |
| US7342119B2 (en) * | 2003-09-30 | 2008-03-11 | Wyeth Holdings Corporation | Process for the synthesis of a CPLA2 inhibitor |
| WO2005049566A1 (en) * | 2003-11-17 | 2005-06-02 | Wyeth | Processes for the preparation of n-substituted phthalimides |
| HN2004000536A (es) * | 2003-12-16 | 2009-02-18 | Wyeth Corp | Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles |
| AR048239A1 (es) * | 2004-02-25 | 2006-04-12 | Wyeth Corp | Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| AR053410A1 (es) * | 2004-08-19 | 2007-05-09 | Wyeth Corp | Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios |
| TW200718687A (en) * | 2005-05-27 | 2007-05-16 | Wyeth Corp | Inhibitors of cytosolic phospholipase A2 |
-
2007
- 2007-10-30 BR BRPI0717943-0A2A patent/BRPI0717943A2/pt not_active Application Discontinuation
- 2007-10-30 AU AU2007313706A patent/AU2007313706A1/en not_active Abandoned
- 2007-10-30 TW TW096140767A patent/TW200824712A/zh unknown
- 2007-10-30 EP EP07871284A patent/EP2104498A2/en not_active Withdrawn
- 2007-10-30 WO PCT/US2007/082966 patent/WO2008055136A2/en not_active Ceased
- 2007-10-30 JP JP2009534934A patent/JP2010508302A/ja not_active Withdrawn
- 2007-10-30 CL CL2007003143A patent/CL2007003143A1/es unknown
- 2007-10-30 US US12/513,071 patent/US20100113443A1/en not_active Abandoned
- 2007-10-31 PE PE2007001502A patent/PE20081408A1/es not_active Application Discontinuation
- 2007-10-31 AR ARP070104829A patent/AR063743A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200824712A (en) | 2008-06-16 |
| AR063743A1 (es) | 2009-02-18 |
| BRPI0717943A2 (pt) | 2013-10-29 |
| PE20081408A1 (es) | 2008-11-04 |
| WO2008055136A2 (en) | 2008-05-08 |
| WO2008055136A3 (en) | 2009-07-23 |
| AU2007313706A1 (en) | 2008-05-08 |
| JP2010508302A (ja) | 2010-03-18 |
| EP2104498A2 (en) | 2009-09-30 |
| US20100113443A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
| CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
| ECSP088222A (es) | Agonistas de receptores adrenérgicos alfa2c funcionalmente selectivos | |
| CL2007002594A1 (es) | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . | |
| MX2008016372A (es) | Composiciones farmaceuticas. | |
| AR070736A1 (es) | Metodos y sistemas para recubrir sustratos | |
| MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
| NO20081160L (no) | Benzimidazoltiofen forbindelser | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| JO2778B1 (en) | Certain Compounds, Compositions and Methods | |
| BRPI0922364A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| CR10277A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| ECSP088759A (es) | Composiciones farmacéuticas | |
| UA108741C2 (uk) | Фармацевтична композиція для екстреної контрацепції | |
| CL2008002539A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| ATE502921T1 (de) | Substituierte indole | |
| NI201100107A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente la cd38 y la citarabina. | |
| MX2011007101A (es) | Composiciones de hidrolizados proteicos que tienen capacidad mejorada para liberar colecistocinina (cck). | |
| EA200970067A1 (ru) | Агонисты ep2 | |
| GB2460597A (en) | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | |
| HN2010000352A (es) | Derivados de ciclopropilamida 978 | |
| HN2008001723A (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
| CL2009000281A1 (es) | Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad. | |
| PA8792401A1 (es) | Fenilendiaminas | |
| ATE459620T1 (de) | Benzimidazolthiophenverbindungen als plk- modulatoren |